mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2020-1-108-117mrj-1001Research ArticleОБЗОРЫREVIEWSТерапевтический потенциал эторикоксиба в клинической практикеThe therapeutic potential of etoricoxib in clinical practiceКаратеевА. Е.KarateevA. E.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

aekarat@yandex.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202021032020141108117Copyright © Каратеев А.Е., 20202020Каратеев А.Е.Karateev A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1001

Эторикоксиб – один из наиболее популярных представителей группы нестероидных противовоспалительных препаратов (НПВП), широко используемый в России и других странах мира. Это высокоселективный ингибитор циклооксигеназы 2, обладающий быстрым и выраженным анальгетическим действием, высоким противовоспалительным потенциалом и способностью влиять на развитие центральной сенситизации – одного из центральных механизмов формирования хронической боли. Лечебный потенциал и безопасность эторикоксиба прошли серьезную проверку в ходе многочисленных масштабных рандомизированных контролируемых исследований (РКИ). Он показал себя как эффективное средство для купирования острой боли (в том числе в стоматологической практике) и острого подагрического артрита, длительного лечения ревматоидного артрита, анкилозирующего спондилита (АС) и остеоартрита (ОА). Метаанализ серии РКИ свидетельствует, что эторикоксиб может быть более эффективным обезболивающим средством при АС и ОА, чем другие НПВП. Эторикоксиб достоверно реже вызывает осложнения со стороны желудочно-кишечного тракта, чем неселективные НПВП. Риск развития кардиоваскулярных катастроф при использовании эторикоксиба не выше, чем на фоне приема неселективных НПВП, таких как диклофенак.

Etoricoxib is one of the most popular representatives of a group of nonsteroidal anti-inflammatory drugs (NSAIDs), which is widely used in Russia and other countries of the world. It is a highly selective cyclooxygenase 2 inhibitor that has a rapid and pronounced analgesic effect, a high antiinflammatory potential, and an ability to affect the development of central sensitization, one of the central mechanisms for chronic pain. The therapeutic potential and safety of etoricoxib have been extensively tested in numerous large-scale randomized controlled trials (RCTs). It has proven to be an effective agent for relief of acute pain (including that in dental practice) and acute gouty arthritis, for long-term treatment of rheumatoid arthritis, ankylosing spondylitis (AS), and osteoarthritis (OA). A meta-analysis of a series of RCTs suggests that etoricoxib may be a more effective analgesic drug for AS and OA than other NSAIDs. Etoricoxib significantly less frequently cause gastrointestinal complications than non-selective NSAIDs. The cardiovascular risk associated with etoricoxib is not higher than that with non-selective NSAIDs such as diclofenac.

нестероидные противовоспалительные препаратыэторикоксибэффективностьбезопасностьжелудочно-кишечный тракткардиоваскулярные осложненияnonsteroidal anti-inflammatory drugsetoricoxibefficacysafetygastrointestinal tractcardiovascular complicationsReferencesVan Hecke O, Torrance N, Smith BH. Chronic pain epidemiology and its clinical relevance. Br J Anaesth. 2013 Jul;111(1):13-8. doi: 10.1093/bja/aet123Van Hecke O, Torrance N, Smith BH. Chronic pain epidemiology and its clinical relevance. Br J Anaesth. 2013 Jul;111(1):13-8. doi: 10.1093/bja/aet123Lestoquoy AS, Laird LD, Mitchell S, et al. Living with chronic pain: Evaluating patient experiences with a medical group visit focused on mindfulness and non-pharmacological strategies. Complement Ther Med. 2017 Dec;35:33-8. doi: 10.1016/j.ctim.2017.09.002. Epub 2017 Sep 12.Lestoquoy AS, Laird LD, Mitchell S, et al. Living with chronic pain: Evaluating patient experiences with a medical group visit focused on mindfulness and non-pharmacological strategies. Complement Ther Med. 2017 Dec;35:33-8. doi: 10.1016/j.ctim.2017.09.002. Epub 2017 Sep 12.Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 446 с. ISBN 978-5-9704-4261-6Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical recommendations. Rheumatology]. Moscow: GEOTAR-Media; 2017. 446 p. (In Russ.). ISBN 978-5-9704-4261-6GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic anlysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic anlysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009–2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-94. doi: 10.1002/acr.22890Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009–2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-94. doi: 10.1002/acr.22890Deyo R, Mirza S, Turner J, Martin B. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009;22(1):62-8. doi: 10.3122/jabfm.2009.01.080102Deyo R, Mirza S, Turner J, Martin B. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009;22(1):62-8. doi: 10.3122/jabfm.2009.01.080102Nagakura Y. The need for fundamental reforms in the pain research field to develop innovative drugs. Expert Opin Drug Discov. 2017 Jan;12(1):39-46. doi: 10.1080/17460441.2017.1261108. Epub 2016 Nov 22.Nagakura Y. The need for fundamental reforms in the pain research field to develop innovative drugs. Expert Opin Drug Discov. 2017 Jan;12(1):39-46. doi: 10.1080/17460441.2017.1261108. Epub 2016 Nov 22.Peppin JF, Cheatle MD, Kirsh KL, McCarberg BH. The complexity model: a novel approach to improve chronic pain care. Pain Med. 2015 Apr;16(4):653-66. doi: 10.1111/pme.12621. Epub 2015 Mar 6.Peppin JF, Cheatle MD, Kirsh KL, McCarberg BH. The complexity model: a novel approach to improve chronic pain care. Pain Med. 2015 Apr;16(4):653-66. doi: 10.1111/pme.12621. Epub 2015 Mar 6.Conaghan PG, Peloso PM, Everett SV, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford). 2015 Feb;54(2): 270-7. doi: 10.1093/rheumatology/keu332. Epub 2014 Aug 23.Conaghan PG, Peloso PM, Everett SV, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford). 2015 Feb;54(2): 270-7. doi: 10.1093/rheumatology/keu332. Epub 2014 Aug 23.Picavet HSJ, Monique Verschuren WM, Groot L, et al. Pain over the adult life course: 15-year pain trajectories – The Doetinchem Cohort Study. Eur J Pain. 2019 Oct;23(9): 1723-32. doi: 10.1002/ejp.1450. Epub 2019 Jul 25.Picavet HSJ, Monique Verschuren WM, Groot L, et al. Pain over the adult life course: 15-year pain trajectories – The Doetinchem Cohort Study. Eur J Pain. 2019 Oct;23(9): 1723-32. doi: 10.1002/ejp.1450. Epub 2019 Jul 25.Bastick AN, Wesseling J, Damen J, et al. Defining knee pain trajectories in early symptomatic knee osteoarthritis in primary care: 5-year results from a nationwide prospective cohort study (CHECK). Br J Gen Pract. 2016 Jan;66(642):e32-9. doi: 10.3399/bjgp15X688129. Epub 2015 Dec 6.Bastick AN, Wesseling J, Damen J, et al. Defining knee pain trajectories in early symptomatic knee osteoarthritis in primary care: 5-year results from a nationwide prospective cohort study (CHECK). Br J Gen Pract. 2016 Jan;66(642):e32-9. doi: 10.3399/bjgp15X688129. Epub 2015 Dec 6.Fornasari D. Pain mechanisms in patients with chronic pain. Clin Drug Investig. 2012 Feb;32 Suppl 1:45-52. doi: 10.2165/11630070-000000000-00000Fornasari D. Pain mechanisms in patients with chronic pain. Clin Drug Investig. 2012 Feb;32 Suppl 1:45-52. doi: 10.2165/11630070-000000000-00000Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018 Feb;22(2): 216-41. doi: 10.1002/ejp.1140Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018 Feb;22(2): 216-41. doi: 10.1002/ejp.1140Vardeh D, Mannion RJ, Woolf CJ. Toward a mechanism-based approach to pain diagnosis. J Pain. 2016 Sep;17(9 Suppl): T50-69. doi: 10.1016/j.jpain.2016.03.001Vardeh D, Mannion RJ, Woolf CJ. Toward a mechanism-based approach to pain diagnosis. J Pain. 2016 Sep;17(9 Suppl): T50-69. doi: 10.1016/j.jpain.2016.03.001Salaffi F, Giacobazzi G, Di Carlo M. Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets – A focus on the JAK-STAT pathway. Pain Res Manag. 2018 Feb 7;2018:8564215. doi: 10.1155/2018/8564215. eCollection 2018.Salaffi F, Giacobazzi G, Di Carlo M. Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets – A focus on the JAK-STAT pathway. Pain Res Manag. 2018 Feb 7;2018:8564215. doi: 10.1155/2018/8564215. eCollection 2018.Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019 Jun;15(6):355-63. doi: 10.1038/s41584-019-0221-yConaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019 Jun;15(6):355-63. doi: 10.1038/s41584-019-0221-yКаратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др.; Ассоциация ревматологов России, Российское общество по изучению боли, Российская гастроэнтерологическая ассоциация, Российское научное медицинское общество терапевтов, Ассоциация травматологов-ортопедов России, Российская ассоциация паллиативной медицины. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации.. Научно-практическая ревматология. 2018; 56 Прил. 1:1-29. doi: 10.14412/1995-4484-2018-1-29Karateev AE, Nasonov EL, Ivashkin VT, et al; Association of Rheumatologists of Russia, Russian Society for the Study of Pain, Russian Gastroenterology Association, Russian Scientific Medical Society of Therapists, Association of Traumatologists and Orthopedists of Russia, Russian Association of Palliative Medicine. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56 Suppl. 1:1-29. doi: 10.14412/1995-4484-2018-1-29 (In Russ.).Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta. 2015 Apr;1851(4): 414-21. doi: 10.1016/j.bbalip.2014.07.008. Epub 2014 Jul 17.Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta. 2015 Apr;1851(4): 414-21. doi: 10.1016/j.bbalip.2014.07.008. Epub 2014 Jul 17.Grö sch S, Niederberger E, Geisslinger G. Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain. Expert Opin Investig Drugs. 2017 Jan;26(1):51-61. doi: 10.1080/13543784.2017.1260544. Epub 2016 Nov 20.Grö sch S, Niederberger E, Geisslinger G. Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain. Expert Opin Investig Drugs. 2017 Jan;26(1):51-61. doi: 10.1080/13543784.2017.1260544. Epub 2016 Nov 20.Salvado MD, Alfranca A, Haeggström JZ, Redondo JM. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol Med. 2012 Apr;18(4):233-43. doi: 10.1016/j.molmed.2012.02.002. Epub 2012 Mar 17.Salvado MD, Alfranca A, Haeggström JZ, Redondo JM. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol Med. 2012 Apr;18(4):233-43. doi: 10.1016/j.molmed.2012.02.002. Epub 2012 Mar 17.Nadda N, Vaish V, Setia S, Sanyal SN. Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Biomed Pharmacother. 2012 Sep;66(6):474-83. doi: 10.1016/j.biopha.2012.04.002. Epub 2012 May 10.Nadda N, Vaish V, Setia S, Sanyal SN. Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Biomed Pharmacother. 2012 Sep;66(6):474-83. doi: 10.1016/j.biopha.2012.04.002. Epub 2012 May 10.Kim HS, Kim T, Kim MK, et al. Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia. J Cancer Prev. 2013 Jun;18(2):123-34. doi: 10.15430/JCP. 2013.18.2.123Kim HS, Kim T, Kim MK, et al. Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia. J Cancer Prev. 2013 Jun;18(2):123-34. doi: 10.15430/JCP. 2013.18.2.123Tanwar L, Piplani H, Sanyal S. Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochlorideinduced colon carcinogenesis. Asian Pac J Cancer Prev. 2010;11(5):1329-33.Tanwar L, Piplani H, Sanyal S. Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochlorideinduced colon carcinogenesis. Asian Pac J Cancer Prev. 2010;11(5):1329-33.Dong X, Hu Y, Jing L, Chen J. Role of phosphorylated extracellular signal-regulated kinase, calcitonin gene-related peptide and cyclooxygenase-2 in experimental rat models of migraine. Mol Med Rep. 2015 Aug;12(2): 1803-9. doi: 10.3892/mmr.2015.3616. Epub 2015 Apr 15.Dong X, Hu Y, Jing L, Chen J. Role of phosphorylated extracellular signal-regulated kinase, calcitonin gene-related peptide and cyclooxygenase-2 in experimental rat models of migraine. Mol Med Rep. 2015 Aug;12(2): 1803-9. doi: 10.3892/mmr.2015.3616. Epub 2015 Apr 15.Eisenach JC, Curry R, Tong C, et al. Effects of intrathecal ketorolac on human experimental pain. Anesthesiology. 2010 May; 112(5):1216-24. doi: 10.1097/ALN. 0b013e3181d94d8bEisenach JC, Curry R, Tong C, et al. Effects of intrathecal ketorolac on human experimental pain. Anesthesiology. 2010 May; 112(5):1216-24. doi: 10.1097/ALN. 0b013e3181d94d8bJakubowski M, Levy D, Kainz V, et al. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience. 2007 Aug 24;148(2): 573-83. doi: 10.1016/j.neuroscience.2007.04.064. Epub 2007 Jul 25.Jakubowski M, Levy D, Kainz V, et al. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience. 2007 Aug 24;148(2): 573-83. doi: 10.1016/j.neuroscience.2007.04.064. Epub 2007 Jul 25.Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005;39(5):854-62. doi: 10.1345/aph.1E543Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005;39(5):854-62. doi: 10.1345/aph.1E543Malmstrom K, Sapre A, Couglin H, et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther. 2004 May; 26(5):667-79. doi: 10.1016/S0149-2918(04) 90067-7Malmstrom K, Sapre A, Couglin H, et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther. 2004 May; 26(5):667-79. doi: 10.1016/S0149-2918(04) 90067-7Kwiatkowska B, Majdan M, Mastalerz-Migas A, et al. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017;55(6): 290-7. doi: 10.5114/reum.2017.72626. Epub 2017 Dec 30.Kwiatkowska B, Majdan M, Mastalerz-Migas A, et al. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017;55(6): 290-7. doi: 10.5114/reum.2017.72626. Epub 2017 Dec 30.Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015 Sep 28;(9):CD008659. doi: 10.1002/14651858.CD008659.pub3Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015 Sep 28;(9):CD008659. doi: 10.1002/14651858.CD008659.pub3Moore RA, Straube S, Paine J, et al. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain. 2011 May; 152(5):982-9. doi: 10.1016/j.pain.2010.11.030Moore RA, Straube S, Paine J, et al. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain. 2011 May; 152(5):982-9. doi: 10.1016/j.pain.2010.11.030Isola G, Matarese G, Alibrandi A, et al. Comparison of effectiveness of etoricoxib and diclofenac on pain and perioperative sequelae after surgical avulsion of mandibular third molars: A randomized, controlled, clinical trial. Clin J Pain. 2019 Nov;35(11):908-15. doi: 10.1097/AJP.0000000000000748Isola G, Matarese G, Alibrandi A, et al. Comparison of effectiveness of etoricoxib and diclofenac on pain and perioperative sequelae after surgical avulsion of mandibular third molars: A randomized, controlled, clinical trial. Clin J Pain. 2019 Nov;35(11):908-15. doi: 10.1097/AJP.0000000000000748Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016 Jan;35(1):151-8. doi: 10.1007/s10067- 015-2991-1. Epub 2015 Jun 24.Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016 Jan;35(1):151-8. doi: 10.1007/s10067- 015-2991-1. Epub 2015 Jun 24.Lin TM, Chi JE, Chang CC, Kang YN. Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A metaanalysis of randomized controlled trials. J Pain Res. 2018 Dec 19;12:83-91. doi: 10.2147/JPR.S186004. eCollection 2019.Lin TM, Chi JE, Chang CC, Kang YN. Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A metaanalysis of randomized controlled trials. J Pain Res. 2018 Dec 19;12:83-91. doi: 10.2147/JPR.S186004. eCollection 2019.Bickham K, Kivitz AJ, Mehta A, et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of rheumatoid arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016 Aug 8;17:331. doi: 10.1186/s12891-016-1170-0Bickham K, Kivitz AJ, Mehta A, et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of rheumatoid arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016 Aug 8;17:331. doi: 10.1186/s12891-016-1170-0Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal antiinflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016 Jun;75(6): 1152-60. doi: 10.1136/annrheumdis-2015-207677. Epub 2015 Aug 6.Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal antiinflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016 Jun;75(6): 1152-60. doi: 10.1136/annrheumdis-2015-207677. Epub 2015 Aug 6.Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal antiinflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016 May 21; 387(10033):2093-105. doi: 10.1016/S0140-6736(16)30002-2Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal antiinflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016 May 21; 387(10033):2093-105. doi: 10.1016/S0140-6736(16)30002-2Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018 Nov;28(6):1021-8. doi: 10.1080/14397595.2018.1439694. Epub 2018 Mar 1.Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018 Nov;28(6):1021-8. doi: 10.1080/14397595.2018.1439694. Epub 2018 Mar 1.Zacher J, Feldman D, Gerli R, et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin. 2003;19(8):725-36. doi: 10.1185/030079903125002469Zacher J, Feldman D, Gerli R, et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin. 2003;19(8):725-36. doi: 10.1185/030079903125002469Reginster J, Malmstrom K, Mehta A, et al. Evalution of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007;66(7): 945-51. doi: 10.1136/ard.2006.059162Reginster J, Malmstrom K, Mehta A, et al. Evalution of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007;66(7): 945-51. doi: 10.1136/ard.2006.059162Давыдов ОС. Периферические и центральные механизмы перехода острой боли в хроническую и возможная роль ингибирования ЦОГ 2 в предотвращении хронизации болевого синдрома. Неврология, нейропсихиатрия, психосоматика. 2016;8(2):10-6. doi: 10.14412/2074-2711- 2016-2-10-16Davydov OS. The peripheral and central mechanisms of transition of acute to chronic pain and the possible role of cyclooxygenase2 inhibition in the prevention of pain syndrome chronization. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2016;8(2):10-6. doi: 10.14412/2074-2711-2016-2-10-16 (In Russ.).Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017;25(11):1781-91. doi: 10.1016/j.joca.2017.07.009Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017;25(11):1781-91. doi: 10.1016/j.joca.2017.07.009Ramey D, Watson D, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005; 21(5):715-22. doi: 10.1185/030079905X43686Ramey D, Watson D, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005; 21(5):715-22. doi: 10.1185/030079905X43686Hunt R, Harper S, Watson D, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003;98(8): 1725-33. doi: 10.1111/j.1572-0241.2003.07598.xHunt R, Harper S, Watson D, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003;98(8): 1725-33. doi: 10.1111/j.1572-0241.2003.07598.xWatson D, Bolognese J, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin. 2004;20(12):1899-908. doi: 10.1185/030079904X12681Watson D, Bolognese J, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin. 2004;20(12):1899-908. doi: 10.1185/030079904X12681Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One. 2018 Jan 10; 13(1):e0190798. doi: 10.1371/journal.pone.0190798. eCollection 2018.Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One. 2018 Jan 10; 13(1):e0190798. doi: 10.1371/journal.pone.0190798. eCollection 2018.Каратеев АЕ, Погожева ЕЮ, Филатова ЕС, Амирджанова ВН. Эндоскопическая картина верхних отделов желудочнокишечного тракта на фоне приема различных нестероидных противовоспалительных препаратов. Клиническая фармакология и терапия. 2018;27(4):40-5.Karateev AE, Pogozheva EYu, Filatova ES, Amirdzhanova VN. Endoscopic picture of the upper gastrointestinal tract while taking various non-steroidal anti-inflammatory drugs. Klinicheskaya farmakologiya i terapiya. 2018;27(4):40-5 (In Russ.).Curtis S, Ko A, Bolognese J, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin. 2006;22(12):2365-74. doi: 10.1185/030079906X148238Curtis S, Ko A, Bolognese J, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin. 2006;22(12):2365-74. doi: 10.1185/030079906X148238Cannon C, Sean P Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368:1771-81. doi: 10.1016/S0140-6736(06)69666-9Cannon C, Sean P Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368:1771-81. doi: 10.1016/S0140-6736(06)69666-9Lin H, Cheng T, Wang J, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010;13(2):144-50. doi: 10.1111/j.1756-185X.2010.01468.xLin H, Cheng T, Wang J, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010;13(2):144-50. doi: 10.1111/j.1756-185X.2010.01468.xКаратеев АЕ. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018;12(2): 64-72. doi: 10.14412/1996-7012-2018-2-64-72Karateev AE. Destabilized hypertension as a complication of therapy with nonsteroidal anti-inflammatory drugs: the importance of the problem. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2018;12(2): 64-72. doi: 10.14412/1996-7012-2018-2-64-72 (In Russ.).Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9Kristensen LE, Jakobsen AK, Askling J, et al. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2015 Aug;67(8): 1137-49. doi: 10.1002/acr.22555Kristensen LE, Jakobsen AK, Askling J, et al. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2015 Aug;67(8): 1137-49. doi: 10.1002/acr.22555Zingler G, Hermann B, Fischer T, Herdegen T. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Exp Rev Clin Pharmacol. 2016 Sep 8:1-14.Zingler G, Hermann B, Fischer T, Herdegen T. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Exp Rev Clin Pharmacol. 2016 Sep 8:1-14.

The authors declare that there are no conflicts of interest present.